Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- XGTI +17.2%, WB +11.2%, GILT +7.4%, SINA +7.3%, VRAY +7.1%, MGIC +6.5%, CLBS +5.6%, BDSI +5%, SPHS +4.6%, VOD +4%, NNA +3.6%, CCUR +3.3%, VIPS +2.5%, NCSM +2.1%, WYY +2%, FATE +1.7%, HD +1.6%, GAIN +1%, CAPR +0.8%
Select oil/gas related names showing strength:
- TOT +1.6%, BP +1.1%, RDS.A +0.9%, CHK +0.7%
Other news:
- AKBA +16.1% (Akebia Therapeutics to sell vadadustat to Fresenius Medical Care)
- ETSY +10.4% (TPG Group Holdings discloses 4.3% active stake, believes Etsy will be best served by a commitment from partners who are also focused on creating long-term value in both public and private companies)
- CNDT +3.8% (Icahn, Greenlight, Sessa, Soros, Scopia among names that disclosed new positions in their quarterly filings)
- ANTH +2.4% (commences screening in the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis; Top line data expected end of 2017 or early 2018 )
- JCP +2.3% (Saba Capital Management discloses new position)
- MOMO +1.5% (Jericho Capital reports new position)
- EPR +1.2% (CEO featured on Monday's Mad Money)
- BIVV +1.1% (ValueAct, Sarissa, Baker Bros disclose new positions)
- LOW +1.1% (in smypathy with HD earnings)
Analyst comments:
- ALDR +4.2% (initiated with Buy at Needham)
- DK +2.6% (upgraded to Buy from Neutral at Goldman)
- SAGE +1.8% (initiated with Buy at Needham)
- EDU +1.8% (upgraded to Buy from Neutral at Goldman)
- AIG +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- DPS +1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ISRG +0.5% (initiated with a Buy at Goldman)